SEP 28, 2015 1:12 PM PDT

Combining Antidepressants with Blood Thinners to Slow Brain Cancer

WRITTEN BY: Ilene Schneider
EPFL approached the problem of treating gliomas by combining tricyclic antidepressants with anticoagulant drugs.Scientists from the Ecole Polytechnique Federale De Lausanne (EPFL) have discovered that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice. The study is published in Cancer Cell and reported in Drug Discovery & Development
 
Aggressive brain tumors coming from the brain’s supporting glial cells, gliomas account for about a third of all brain tumors. They have the highest incidence and mortality rate among primary brain cancer patients, spurring an urgent need for effective treatments. While antidepressants already available could lower the risk of gliomas, there was little evidence to support their use in patients. Scientists at EPFL have discovered that tricyclic antidepressants combined with anticoagulant drugs can actually decelerate gliomas by causing the cancer cells to eat themselves.
 
Gliomas arise from the glial cells when they begin to grow uncontrollably. Normally, glial cells keep the brain’s neurons in place and help them function properly. There are three types of glial cells, and glioma tumors can contain a mixture of them.
 
There is currently little in the way of treatment for gliomas. Since the early 2000s, scientists have considered tricyclic antidepressants as a way to lower the risk of gliomas, but a small clinical trial showed them to offer little benefit to glioma patients.
 
The laboratory of Douglas Hanahan at EPFL approached the problem by combining tricyclic antidepressants with anticoagulant drugs (blood thinners). A study designed and led by Ksenya Shchors screened anti-depressants in combination with several commercially available drugs known to have similar effects on glioma cells. It revealed anticoagulants as the most likely ally.
 
The team determined the effects of the two drugs in mice with gliomas. The researchers gave the animals a combination therapy with different doses of the drugs. The antidepressant was administered orally, and the anticoagulant was injected 10 to 15 minutes later, and each combination therapy ran for five consecutive days.
 
The results showed that the drugs disrupt a biochemical pathway in the glioma tumor cells that controls a mechanism known as “autophagy,” which literally means “to eat oneself.” Low-level, controlled autophagy is a recycling mechanism that actually helps the cell to survive under stressful conditions.
 
The two drugs remove control in two different places along the autophagy pathway. Each drug can stimulate autophagy by itself, but neither has any significant impact on the mortality of the mice with glioma. Nonetheless, when the scientists combined the two drugs, the lifespan of the mice doubled. The team is now making plans for early clinical trials.
 
Douglas Hanahan, who warns that it is not clear yet if patients would benefit from such treatment, is optimistic: “It is exciting to envision that combining two relatively inexpensive and non-toxic classes of generic drugs holds promise to make a difference in the treatment of patients with lethal brain cancer. This strategy is at an early stage and requires further considerably more work to assess its full potential.”
 
 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 24, 2021
Clinical & Molecular DX
Test Lets Cancer Patients Track Whether Their Treatment Is Working in Real Time
JUN 24, 2021
Test Lets Cancer Patients Track Whether Their Treatment Is Working in Real Time
Researchers from Singapore have created the ExoSCOPE, the world’s first blood test for tracking whether or not a p ...
JUL 08, 2021
Genetics & Genomics
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
JUL 08, 2021
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
Children with Down syndrome have a significantly higher likelihood myeloid leukemia occurring in the first five years of ...
JUL 26, 2021
Genetics & Genomics
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
JUL 26, 2021
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
Many types of cells have to be replenished continuously throughout our lives, and the genome in the nucleus of those cel ...
SEP 27, 2021
Cell & Molecular Biology
Optical Imaging in Tissue with Near-Infrared Dyes
SEP 27, 2021
Optical Imaging in Tissue with Near-Infrared Dyes
Optical Imaging in Tissue with Near-Infrared Dyes Written By Christopher Pratt, PhD   Go Long to See Deeper Imaging ...
SEP 22, 2021
Cancer
Whole Genome Sequencing for Cancer Diagnostics
SEP 22, 2021
Whole Genome Sequencing for Cancer Diagnostics
The human genome consists of genetic material known as DNA.  We all have unique DNA sequences made up of four bases ...
OCT 01, 2021
Health & Medicine
Eppendorf Award 2022: Call for Entries
OCT 01, 2021
Eppendorf Award 2022: Call for Entries
Eppendorf Award 2022: Call for Entries The Eppendorf Award for Young European Investigators, endowed with 20,000 EUR, is ...
Loading Comments...